FloStent
Phase 1- Indications
- Benign prostatic hyperplasia, Urinary retention
Company intelligence / Profile preview
Rivermark Medical’s FloStent System has demonstrated successful first-in-human use and completion of a multi-center OUS clinical trial. The pivotal RAPID III study is ongoing in North America and Australia, evaluating safety and effectiveness for men with BPH. Early results indicate the device can rapidly restore urinary flow, minimize recovery time, preserve sexual function, and maintain future treatment options. Expanded indication studies have also been conducted in patients with urinary retention due to BPH.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rivermark Medical.